December 05, 2020
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of Ibrutinib plus Venetoclax confers high rates of peripheral blood and bone marrow undetectable minimal residual disease in patients with CLL, and a 90% reduction in high-risk tumor lysis syndrome monitoring.
Wierda WG, Tam CS, Allan JN, Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study (Abstract 123). https://ash.confex.com/ash/2020/webprogram/Paper134446.html. December 5, 2020.